Gastrointestinal cancer treatment using PRMT5 inhibitors in conjunction with MTA.

By combining compound G with other anticancer drugs, the targeting problem of MTAP-resistant gastrointestinal cancer has been solved, improving treatment efficacy and reducing the impact on normal tissues, particularly for pancreatic adenocarcinoma and biliary tract cancer.

CN123076381APending Publication Date: 2026-11-10AMGEN INC
View PDF 26 Cites 0 Cited by

Patent Information

Application Number
CN202580025890.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-05
Filing Date
2025-04-07
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively target PRMT5 in MTAP-ineffective tumors without affecting PRMT5 in normal tissues, resulting in poor treatment outcomes for MTAP-ineffective gastrointestinal cancers.

Method used

Compound G and its pharmaceutically acceptable salts are used in combination with other anticancer drugs (such as gemcitabine, paclitaxel, irinotecan, 5-fluorouracil, leucovorin, oxaliplatin, cisplatin, anti-PD1 antibody or anti-PDL1 antibody) to treat MTAP-resistant gastrointestinal cancer.

Benefits of technology

It improves the treatment efficacy of MTAP-resistant gastrointestinal cancers, especially the treatment index of pancreatic adenocarcinoma and biliary tract cancer, and reduces side effects on normal tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_17
    Figure SMS_17
  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
Patent Text Reader

Abstract

This article describes a method for treating patients with MTAP-resistant gastrointestinal cancer, which includes administering a PRMT5 inhibitor, gemcitabine, and paclitaxel (e.g., albumin-bound paclitaxel), or a PRMT5 inhibitor and mFOLFIRINOX. This article also describes a method for treating patients with MTAP-resistant gastrointestinal cancer, which includes administering a PRMT5 inhibitor, gemcitabine, cisplatin, and an anti-PD1 antibody or an anti-PDL1 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to each of U.S. Provisional Patent Application No. 63 / 575,379, filed April 5, 2024, and U.S. Provisional Patent Application No. 63 / 575,402, filed April 5, 2024. Background Technology

[0003] Epigenetic regulation of gene expression is a crucial biological determinant of protein production and cell differentiation, and plays a significant pathogenic role in many human diseases. Epigenetic regulation involves heritable modifications of genetic material without altering its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modifications (e.g., methylation) of DNA and proteins (e.g., histones), which control conformational transitions between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., PRMT5), many of which are associated with specific genetic alterations that can cause human diseases. PRMT5 plays a role in diseases such as proliferative disorders, metabolic disorders, and blood disorders.

[0004] Homozygous loss of tumor suppressor genes is a key driver in cancer, often leading to the incidental loss of passenger genes located in the genome adjacent to the tumor suppressor. The loss of these passenger genes can create therapeutically vulnerable vulnerabilities specific to tumor cells. Homozygous loss of the chromosome 9p21 locus (carrying the well-known tumor suppressor CDKN2A (cyclin-dependent kinase inhibitor 2A)) occurs in 15% of all tumors and typically includes the passenger gene MTAP (methionine phosphorylase, a key enzyme in the methionine and adenine rescue pathway). MTAP loss leads to the accumulation of its substrate, methionine (MTA). MTA shares close structural similarity with S-adenosylmethionine (SAM) (the methyl donor substrate of the type II methyltransferase PRMT5). Elevated MTA levels driven by MTAP loss selectively compete with SAM for binding to PRMT5, leaving the methyltransferase in a suballelic state, vulnerable to further PRMT5 inhibition. Multiple genome-wide shRNA dropout screening in large tumor cell lines has identified a strong correlation between MTAP loss and cell line dependence on PRMT5, further highlighting the intensity of this metabolic vulnerability. However, PRMT5 is a known essential cellular gene, and conditional PRMT5 knockout and siRNA knockdown studies have shown that significant burdens (e.g., pancytopenia, infertility, skeletal muscle loss, cardiac hypertrophy, etc.) may be associated with PRMT5 inhibition in normal tissues. Therefore, novel strategies are needed to exploit this metabolic vulnerability and preferentially target PRMT5 in MTAP-null tumors without impairing PRMT5 in normal tissues (MTAP-WT). Targeting PRMT5 with a small molecule inhibitor that works in conjunction with MTA can preferentially target the MTA-binding state of PRMT5 enriched in MTAP-null tumor cells, while providing an improved therapeutic index beyond that of normal cells (where MTAP is intact and MTA levels are low). Summary of the Invention

[0005] In one aspect, this article describes a method for treating MTAP-resistant gastrointestinal cancer in patients in need, comprising administering to the patient a therapeutically effective amount of each of the following: (a) Compound G: (G) or a pharmaceutically acceptable salt thereof; (b) gemcitabine and (c) paclitaxel. In some cases, MTAP-ineffective gastrointestinal cancers are pancreatic adenocarcinomas (e.g., pancreatic ductal adenocarcinoma (PDAC)).

[0006] In another aspect, this article describes a method for treating MTAP-resistant gastrointestinal cancer in patients in need, comprising administering to the patient a therapeutically effective amount of each of the following: (a) Compound G: (G), or a pharmaceutically acceptable salt thereof; and (b) (i) a combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin, and (iv) oxaliplatin. In some cases, MTAP-ineffective gastrointestinal cancers are pancreatic adenocarcinomas (e.g., pancreatic ductal adenocarcinoma (PDAC)).

[0007] In another aspect, this article describes a method for treating MTAP-resistant gastrointestinal cancer in patients in need, which involves administering to the patient a therapeutically effective dose of each of the following:

[0008] (a) Compound G: (G) or a pharmaceutically acceptable salt thereof; (b) gemcitabine; (c) cisplatin; and (d) an anti-PD1 antibody or an anti-PDL1 antibody. In some cases, the anti-PD1 antibody is pembrolizumab. In some cases, the MTAP-resistant gastrointestinal cancer is biliary tract cancer. Detailed Implementation

[0009] This disclosure provides a method for treating MTAP-resistant gastrointestinal cancer in patients in need. In one aspect, this disclosure provides a method for treating MTAP-resistant gastrointestinal cancer in patients in need, the method comprising administering to the patient a therapeutically effective amount of each of the following: (a) compound G, (G), or a pharmaceutically acceptable salt thereof; (b) gemcitabine and (c) paclitaxel. In another aspect, this disclosure also provides a method for treating MTAP-resistant gastrointestinal cancer in patients in need, the method comprising administering to the patient a therapeutically effective amount of each of the following: (a) compound G: (G), or a pharmaceutically acceptable salt thereof; and (b) (i) a combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin, and (iv) oxaliplatin. In another aspect, this disclosure provides a method for treating MTAP-resistant gastrointestinal cancer in patients in need, the method comprising administering to the patient a therapeutically effective amount of each of the following: (a) compound G: (G), or a pharmaceutically acceptable salt thereof; (b) gemcitabine; (c) cisplatin; and (d) an anti-PD1 antibody or an anti-PDL1 antibody. As used herein, a “therapeuticly effective amount” of a compound disclosed herein (e.g., compound G) means an amount that effectively treats, alleviates, or stabilizes the disease or symptoms of a patient being treated, or alleviates existing symptoms of a patient being treated.

[0010] This article further provides therapeutically effective amounts of each of the following: (a) compound G, or a pharmaceutically acceptable salt thereof; (b) gemcitabine and (c) paclitaxel, for use in the treatment of MTAP-ineffective gastrointestinal cancer in patients in need. This article also provides therapeutically effective amounts of each of the following: (a) compound G, or a pharmaceutically acceptable salt thereof; and (b) (i) a combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin and (iv) oxaliplatin, for use in the treatment of MTAP-ineffective gastrointestinal cancer in patients in need. This article further provides therapeutically effective amounts of each of the following: (a) compound G, or a pharmaceutically acceptable salt thereof; (b) gemcitabine; (c) cisplatin; and (d) an anti-PD1 antibody or an anti-PDL1 antibody, for use in the treatment of MTAP-ineffective gastrointestinal cancer in patients in need. This article also provides for the use of each of the following in therapeutically effective amounts in the manufacture of a medicament for the treatment of patients with MTAP-resistant gastrointestinal cancer in need: (a) compound G, or a pharmaceutically acceptable salt thereof; (b) gemcitabine and (c) paclitaxel. This article further provides for the use of each of the following in therapeutically effective amounts in the manufacture of a medicament for the treatment of patients with MTAP-resistant gastrointestinal cancer in need: (a) compound G, or a pharmaceutically acceptable salt thereof; and (b) (i) a combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin and (iv) oxaliplatin. This article also provides for the use of each of the following in therapeutically effective amounts in the manufacture of a medicament for the treatment of patients with MTAP-resistant gastrointestinal cancer in need: (a) compound G, or a pharmaceutically acceptable salt thereof; (b) gemcitabine; (c) cisplatin; and (d) an anti-PD1 antibody or an anti-PDL1 antibody.

[0011] In some cases, in the methods disclosed herein, compound G is administered as a free base. In some cases, in the methods disclosed herein, compound G is administered as a pharmaceutically acceptable salt. Pharmaceutically acceptable salts of the compounds described herein (e.g., compound G) include those derived from suitable inorganic and organic acids and inorganic and organic bases. Pharmaceutically acceptable salts include those with inorganic acids (such as hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, metaphosphoric acid, nitric acid, and sulfuric acid) and with organic acids (such as tartaric acid, acetic acid, trifluoroacetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, formic acid, propionic acid, glycolic acid, gluconic acid, maleic acid, succinic acid, camphor sulfonic acid, isothiocyanate, mucilage, gentianic acid, isonicotinic acid, succinic acid, glucuronic acid, furoic acid, glutamic acid, ascorbic acid, anthranilic acid, salicylic acid, etc.). Acid addition salts formed with phenylacetic acid, mandelic acid, embol acid, methanesulfonic acid, ethanesulfonic acid, pantothenic acid, stearic acid, sulfinic acid, alginic acid, galacturonic acid, and arylsulfonic acids (e.g., benzenesulfonic acid and p-toluenesulfonic acid); base addition salts formed with alkali metals and alkaline earth metals, as well as organic bases (such as N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucosamine), lysine, and procaine); and salts formed internally. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (ed.), Handbook of Pharmaceutical Salts Properties, Selection and Use; 2002. In various embodiments, compound G or its salts are administered orally.

[0012] Pharmaceutical compositions containing compound G can be manufactured in a conventional manner, such as through conventional mixing, dissolving, granulation, sugar-coated pellet preparation, grinding, emulsification, encapsulation, embedding, or lyophilization processes. In various cases, compound G is administered orally. In some cases, compound G is administered as a tablet formulation.

[0013] In some embodiments, compound G or a pharmaceutically acceptable salt thereof is administered orally and once daily to a patient in need. The term "patient" or "subject" contemplated for administration includes, but is not limited to, humans (i.e., men or women of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)). In some embodiments, the subject is a human. In various embodiments, the subject is a non-human animal. The terms "patient" and "subject" are used interchangeably herein.

[0014] In some embodiments, compound G is administered orally. In some embodiments, compound G is administered orally once daily. In some embodiments, compound G is administered orally twice daily. In some embodiments, a total daily dose of 100 mg, 120 mg, 200 mg, 240 mg, 300 mg, 400 mg, 480 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, or 1600 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 120 mg, 200 mg, 240 mg, 300 mg, 400 mg, 480 mg, 500 mg, 600 mg, 800 mg, 900 mg, 1200 mg, or 1600 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 400 mg, 500 mg, 600 mg, 800 mg, or 1200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 500 mg, 800 mg, 900 mg, or 1200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 500 mg, 800 mg, or 1200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 800 mg, 900 mg, or 1200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 800 mg or 1200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 120 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 200 mg of compound G is administered to the patient based on the weight of the free base of compound G. In some embodiments, a total daily dose of 240 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 300 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 400 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 480 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 500 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 600 mg of compound G is administered to the patient based on the weight of its free base.In some embodiments, a total daily dose of 700 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 800 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 900 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 1000 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 1100 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 1200 mg of compound G is administered to the patient based on the weight of its free base. In some embodiments, a total daily dose of 1600 mg of compound G is administered to the patient based on the weight of its free base.

[0015] In some embodiments, 100 mg, 120 mg, 200 mg, 240 mg, 300 mg, 400 mg, 480 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, or 1600 mg of compound G is administered to a patient once daily, based on the weight of the free base of compound G. In some embodiments, 120 mg, 200 mg, 240 mg, 300 mg, 400 mg, 480 mg, 500 mg, 600 mg, 800 mg, 900 mg, 1200 mg, or 1600 mg of compound G is administered to a patient once daily, based on the weight of the free base of compound G. In some embodiments, 400 mg, 500 mg, 600 mg, 800 mg, or 1200 mg of compound G is administered to a patient once daily, based on the weight of the free base of compound G. In some embodiments, 500 mg, 800 mg, 900 mg, or 1200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 500 mg, 800 mg, or 1200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 800 mg, 900 mg, or 1200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 800 mg or 1200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 120 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 240 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 300 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 400 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 480 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 500 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 600 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 700 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 800 mg of compound G is administered to the patient once daily, based on the weight of its free base.In some embodiments, 900 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 1000 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 1100 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 1200 mg of compound G is administered to the patient once daily, based on the weight of its free base. In some embodiments, 1600 mg of compound G is administered to the patient once daily, based on the weight of its free base.

[0016] When a dose or amount of compound G is listed, unless otherwise stated, it refers to the amount of compound G based on the weight of its free base. For example, when this document discloses administration of 400 mg of compound G or a salt thereof to a patient, 400 mg is the amount of compound G based on the weight of its free base. It should be understood that if a salt of compound G is administered to a patient, the weight of the amount of the salt of compound G will be higher to compensate for the weight of the salt entity.

[0017] In some embodiments, compound G is administered during a treatment cycle. In some embodiments, the treatment cycle is 28 days. In some embodiments, the 28-day treatment cycle is repeated. In various embodiments, the patient experiences 1, 2, 3, or more 28-day treatment cycles. In some embodiments, the patient experiences at least three, at least five, at least eight, at least ten, or at least fifteen 28-day treatment cycles. In some cases, the method disclosed herein for treating MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC) includes administering compound G during one or more 28-day treatment cycles.

[0018] In some embodiments, the treatment cycle is 21 days. In some embodiments, the 21-day treatment cycle is repeated. In various embodiments, the patient experiences 1, 2, 3, or more 21-day treatment cycles. In some embodiments, the patient experiences at least three 21-day treatment cycles, at least five 21-day treatment cycles, at least eight 21-day treatment cycles, at least ten 21-day treatment cycles, or at least fifteen 21-day treatment cycles. In some cases, the method disclosed herein for treating MTAP-resistant biliary tract cancer includes administering compound G during one or more 21-day treatment cycles.

[0019] Giscitabine

[0020] Gemcitabine (GEMZAR®) is a nucleoside analogue exhibiting antitumor activity. See GEMZAR® USPrescribing Information, Eli Lily & Co., Indianapolis, IN 46285 (revised May 2019), which is incorporated herein by reference in its entirety.

[0021] In some embodiments, these methods include administering 1000 mg / m² to the patient. 2 Gemcitabine. In some embodiments, gemcitabine is administered intravenously (“IV administration”). In some embodiments, gemcitabine is administered three times during a 28-day treatment cycle. In some embodiments, the method described herein comprises administering 1000 mg / m² via IV to the patient during each 28-day treatment cycle. 2 Gemcitabine was administered three times. In some embodiments, the method described herein includes administering 1000 mg / m² via IV to the patient on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine. In some cases, these methods involve administering 1000 mg / m² to the patient via IV over one or more 28-day treatment cycles. 2 Gemcitabine was administered three times to treat MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC). In some embodiments, gemcitabine was administered twice during a 21-day treatment cycle. In some embodiments, the method described herein includes administering 1000 mg / m² via IV to the patient during each 21-day treatment cycle. 2 Gemcitabine twice. In some embodiments, the method described herein includes administering 1000 mg / m² to the patient via IV on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine. In some cases, these methods involve administering 1000 mg / m² to the patient via IV over one or more 21-day treatment cycles. 2 Gemcitabine was administered three times to treat MTAP-resistant biliary tract cancer.

[0022] Paclitaxel

[0023] Paclitaxel is a semi-synthetic taxane, a class of anticancer agents that bind to β-tubulin, thereby stabilizing microtubules and inducing cell cycle arrest and apoptosis. Paclitaxel in combination with carboplatin 200 mg / m² 2 Intravenous administration every 3 weeks over 3 hours is the standard treatment option for patients with advanced or metastatic, previously untreated PDAC who are in good physical condition.

[0024] Complete information on the preparation, reconstitution, dosage, and administration schedule of paclitaxel (TAXOL®) can be found in the local package insert (for the United States, see, for example, TAXOL® INJECTION US Prescribing Information, Bristol-Myers Squibb Company, Princeton, New Jersey, 08543 (revised April 2011)), which is incorporated herein by reference in its entirety. In some embodiments, paclitaxel administered to a patient is bound to albumin (“nab-paclitaxel”). Complete information on the preparation, dispensing, dosage, and administration schedule of albumin-bound paclitaxel (ABRAXANE®) can be found in the local package insert (for the United States, see, for example, ABRAXANE® US Prescribing Information, Bristol-Myers Squibb, NY 08543 (revised August 2020), which is incorporated herein by reference in its entirety).

[0025] In some embodiments, these methods include administering paclitaxel to a patient. In some embodiments, the paclitaxel is albumin-bound paclitaxel. In some embodiments, paclitaxel (e.g., albumin-bound paclitaxel) is administered intravenously (“via IV”). In some embodiments, paclitaxel (e.g., albumin-bound paclitaxel) is administered three times during a 28-day treatment cycle. In some embodiments, the methods described herein include administering 125 mg / m² via IV to a patient during each 28-day treatment cycle. 2 Paclitaxel (e.g., albumin-bound paclitaxel) three times. In some embodiments, the method described herein includes administering 125 mg / m² to the patient via IV on days 1, 8, and 15 of a 28-day treatment cycle. 2 Paclitaxel (e.g., albumin-bound paclitaxel). In some embodiments, paclitaxel (e.g., albumin-bound paclitaxel) is administered to treat MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC).

[0026] FOLFIRINOX

[0027] In some embodiments, the methods described herein include administering a FOLFIRINOX-based regimen to a patient. In some embodiments, the methods described herein include administering a modified FOLFIRINOX regimen (“mFOLFIRINOX”) to a patient. FOLFIRINOX is a combination therapy comprising leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin. Modified FOLFIRINOX, or mFOLFIRINOX, is a combination regimen containing calcium leucovorin, 5-fluorouracil, irinotecan hydrochloride, and oxaliplatin. Compared to FOLFIRINOX, mFOLFIRINOX does not involve a fluorouracil bolus, and the irinotecan dose starts from 180 mg / m². 2 Reduced to 150 mg / m 2 The terms “leucovorin,” “calcium leucovorin,” “5-formyl-tetrahydrofolate,” and “LV” are used interchangeably in this document. The terms “irinotecan” and “irinotecan hydrochloride” are used interchangeably in this document. The terms “fluorouracil,” “5-fluorouracil,” “FU,” and “5-FU” are used interchangeably in this document. See also: CALCIUM FOLINATE / Leucovorin Calcium, US Prescribing Information, Bedford Laboratories, Bedford, OH, 44146 (revised November 2011); CAMPTOSTAR® (irinotecan), US Prescribing Information, Pfizer, Inc., New York, NY, 10017 (revised December 2014); ELOXATIN® (oxaliplatin), US Prescribing Information, Pfizer, NY, 1017 (revised April 2016); and fluorouracil, US Prescribing Information, Fresenius Kabi, Lake Zurich. Illinois (IL), 60047 (revised February 2024), whose disclosures are incorporated herein by reference in their entirety.

[0028] In some embodiments, the method described herein includes administering 150 mg / m² to a patient. 2Irinotecan. In some embodiments, irinotecan is administered intravenously. In some embodiments, irinotecan is administered twice during a 28-day treatment cycle. In some embodiments, the method described herein includes administering 150 mg / m² to the patient intravenously during a 28-day treatment cycle. 2 Irinotecan twice. In some embodiments, the method described herein includes administering 2400 mg / m² to the patient. 2 5-Fluorouracil. In some embodiments, 5-fluorouracil is administered intravenously. In some embodiments, 5-fluorouracil is administered twice during a 28-day treatment cycle. In some embodiments, the method described herein includes administering 2400 mg / m² to the patient intravenously during a 28-day treatment cycle. 2 5-Fluorouracil twice. In some embodiments, the method described herein includes administering 400 mg / m² to the patient. 2 Follic acid. In some embodiments, follic acid is administered intravenously. In some embodiments, follic acid is administered twice during a 28-day treatment cycle. In some embodiments, the method described herein includes administering 400 mg / m² to the patient intravenously during a 28-day treatment cycle. 2 Folic acid. In some embodiments, the method described herein includes administering 85 mg / m² to a patient. 2 Oxaliplatin. In some embodiments, oxaliplatin is administered intravenously. In some embodiments, oxaliplatin is administered twice during a 28-day treatment cycle. In some embodiments, the method described herein includes administering 85 mg / m² to the patient intravenously during a 28-day treatment cycle. 2 Oxaliplatin twice. In some embodiments, the method described herein includes administering irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin to the patient on days 1 and 15 of a 28-day cycle.

[0029] In some embodiments, 400 mg / m 2 Folic acid can be 200 mg / m 2 Levofolate substitution (see KHAPZORY® US Prescribing Information, Spectrum Pharmaceuticals, Inc., Irvine, CA 92618 (revised October 2018), which is incorporated herein by reference in its entirety).

[0030] Cisplatin

[0031] Cisplatin (PLATINOL®), cisplatin or cisamine dichloroplatin (II) (CDDP), is a platinum-based chemotherapy drug used to treat a wide range of cancers, including sarcomas, some epithelial carcinomas (e.g., small cell lung cancer and ovarian cancer), lymphomas, and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. See also PLATINOL® US Prescribing Information, Bristol-Myers Squibb, Princeton, NJ, 08543 (revised December 2023), which is incorporated herein by reference in its entirety.

[0032] In some embodiments, the method described herein includes administering 25 mg / m² to a patient. 2 Cisplatin. In some embodiments, cisplatin is administered intravenously. In some embodiments, cisplatin is administered twice during a 21-day treatment cycle. In some embodiments, the method described herein includes administering 25 mg / m² during a 21-day treatment cycle. 2 Cisplatin twice. In some embodiments, the method described herein includes administering 25 mg / m² to the patient via IV on days 1 and 8 of a 21-day treatment cycle. 2 Cisplatin.

[0033] Anti-PD1 and anti-PDL1 antibodies

[0034] Programmed death 1 (PD-1 or PD1) is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS, and BTLA. Anti-PD1 antibodies and methods of use in the treatment of disease are described in U.S. Patent Nos. 7,595,048; 8,168,179; 8,728,474; 7,722,868; 8,008,449; 7,488,802; 7,521,051; 8,088,905; 8,168,757; 8,354,509; and U.S. Publications 20110171220; 20110171215; and 20110271358. Combinations of CTLA-4 and PD1 antibodies are described in U.S. Patent No. 9,084,776. Some exemplary anti-PD1 antibodies include tislelizumab, dostarlimab, and toripalimab.

[0035] Nivolumab (OPDIVO®) is a fully human monoclonal antibody against PD-1 marketed by Bristol-Myers Squibb. Other names for nivolumab include BMS-936558, MDX-1106, and ONO-4538. The amino acid sequence of nivolumab, as well as its use and preparation methods, are disclosed in U.S. Patent No. 8,008,449. See also OPDIVO® USPrescribing Information, Bristol-Myers Squibb, Princeton, NJ, 08543 (revised February 2023), which is incorporated herein by reference in its entirety.

[0036] Cimiprimab (LIBTAYO®) is an anti-PD-1 antibody marketed by Regeneron Pharmaceuticals for the treatment of squamous cell carcinoma (CSCC), basal cell carcinoma (BSC), and non-small cell lung cancer (NSCLC). The amino acid sequence of cimiprimab is disclosed in U.S. Patent No. 11,292,842. See also LIBTAYO® USPrescribing Information, Regeneron Pharmaceuticals, Tarrytown, NY, 10591 (revised April 2024), which is incorporated herein by reference in its entirety.

[0037] Pembrolizumab (KEYTRUDA®) is an anti-PD1 antibody marketed by Merck, Inc. for the treatment of lung cancer. The amino acid sequence and method of administration of pembrolizumab are disclosed in U.S. Patent No. 8,168,757. See also KEYTRUDA® US Prescribing Information, Merck, Inc., Kenilworth, NJ, 07033 (revised January 2025), which is incorporated herein by reference in its entirety. In some cases, the method described herein involves administering pembrolizumab to a patient in need. In some cases, pembrolizumab is administered once every 21 days. In some cases, pembrolizumab is administered via IV. In some embodiments, the method described herein involves administering 200 mg of pembrolizumab to a patient once every 21 days (once per 21-day treatment cycle).

[0038] Exemplary anti-PDL1 antibodies are described in WO 2013 / 079174, WO 2015 / 061668, WO 2010 / 089411, WO2007 / 005874, WO 2010 / 036959, WO 2014 / 100079, WO 2013 / 019906, WO 2010 / 077634 and U.S. Patent Nos. 8,552,154, 8,779,108, and 8,383,796. In some embodiments, the anti-PDL1 antibody is avelumab (BAVENCIO®) or durvalumab (INFINZI®). See BAVENCIO® US Prescribing Information, EMD Serono, Inc., Rockland, MA, 02370 (revised November 2024), which is incorporated herein by reference in its entirety. See INFINZI® US Prescribing Information, AstraZeneca UK Ltd., Cambridge, England, CB20AA (revised December 2024), which is incorporated herein by reference in its entirety. Exemplary anti-PDL1 antibodies include, but are not limited to, atezolizumab and durvalumab.

[0039] Dosage regimen

[0040] In some embodiments, the methods described herein include administering to a patient a therapeutically effective amount of (a) compound G or a pharmaceutically acceptable salt thereof, (b) gemcitabine, and (c) paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 120 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 200 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 240 mg of compound G or a salt thereof once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 300 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 400 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 480 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 500 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 600 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 700 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 800 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 900 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 1000 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, and (c) 125 mg / m 2Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 1100 mg of compound G or a salt thereof once daily, (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 1200 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some embodiments, the methods described herein include administering to a patient (a) 1600 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel was administered to patients at a dose of 1000 mg / m² on days 1, 8, and 15 of a 28-day treatment cycle. 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel. In some cases, compound G is administered as a free base in the dosage regimens described herein. In some cases, compound G is administered as a tablet formulation in the dosage regimens described herein. In some cases, compound G is administered as a film-coated tablet. In some cases, the dosage regimen is administered to treat patients with pancreatic adenocarcinoma (e.g., PDAC).

[0041] In some embodiments, the methods described herein include administering to a patient a therapeutically effective amount of each of the following: (a) compound G or a salt thereof, and (b) (i) a combination of irinotecan, (ii) 5-fluorouracil, (iii) leucovorin, and (iv) oxaliplatin, wherein irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin are administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the methods described herein include administering to a patient (a) 120 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 200 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 240 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 25-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 300 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 400 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 480 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 500 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 600 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 700 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 800 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 900 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1000 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1100 mg of compound G or a salt thereof once daily, and (b)(i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1600 mg of compound G or a salt thereof once daily, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with 150 mg / m² 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2Oxaliplatin is administered on days 1 and 15 of a 28-day treatment cycle. In some cases, compound G is administered as a free base in the dosage regimen described herein. In some cases, compound G is administered as a tablet formulation in the dosage regimen described herein. In some cases, compound G is administered as a film-coated tablet. In some cases, the dosage regimen is administered to treat patients with pancreatic adenocarcinoma (e.g., PDAC).

[0042] In some embodiments, the methods described herein include administering to a patient a therapeutically effective amount of each of the following: (a) compound G or a salt thereof, (b) gemcitabine, (c) cisplatin, and (d) pembrolizumab. In some embodiments, the methods described herein include administering to a patient (a) 120 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 200 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein comprises administering to the patient (a) 240 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 300 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein comprises administering to the patient (a) 400 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 480 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 500 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 600 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 700 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 800 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 900 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1000 mg of compound G or a salt thereof once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1100 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, wherein pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some embodiments, the method described herein includes administering to the patient (a) 1600 mg of compound G or a salt thereof once daily, (b) 1000 mg / m² 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, of which 1000 mg / m² was administered to the patient on days 1 and 8 of a 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and in which pembrolizumab is administered once intravenously during a 21-day treatment cycle. In some cases, compound G is administered as a free base in the dosage regimen described herein. In some cases, compound G is administered as a tablet formulation in the dosage regimen described herein. In some cases, compound G is administered as a film-coated tablet. In some cases, the dosage regimen is administered to treat patients with biliary tract cancer.

[0043] The patient's previous treatment plan

[0044] In some embodiments, the patient has not previously received systemic therapy for MTAP-resistant gastrointestinal cancer, such as advanced (metastatic) or unresectable (locally advanced) pancreatic adenocarcinoma (e.g., PDAC), or advanced (metastatic) or unresectable (locally advanced) biliary tract cancer (intrahepatic or extrahepatic bile duct cancer or gallbladder cancer) (i.e., the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer). Therefore, in some cases, these methods are used as first-line therapy for MTAP-resistant gastrointestinal cancer. In some cases, these methods are used as first-line therapy for MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC). In some cases of first-line therapy for MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC), the patient is administered a combination of compound G as disclosed herein and a FOLFIRINOX-based regimen (e.g., mFOLFIRINOX). In some cases of first-line therapy for MTAP-resistant pancreatic adenocarcinoma (e.g., PDAC), the patient is administered a combination of compound G as disclosed herein, gemcitabine, and paclitaxel (e.g., albumin-bound paclitaxel). In some cases, these methods serve as first-line therapy for MTAP-resistant biliary tract cancer. In some cases of first-line therapy for MTAP-resistant biliary tract cancer, patients are administered a combination of compound G, gemcitabine, cisplatin, and an anti-PD1 antibody or an anti-PDL1 antibody, as disclosed herein.

[0045] In some cases, patients have been treated with prior systemic therapies for gastrointestinal cancer as second-line (or higher) therapy, and these patients are not treatment-naïve patients for cancer treated with the methods disclosed herein. In some embodiments, the patient has received at least one systemic therapy for locally advanced or metastatic disease prior to administration of compound G. In some cases, the patient has received prior systemic therapy and received the first dose of the prior systemic therapy within 28 days of signing the primary consent form. In some cases, the prior systemic therapy is a FOLFIRINOX-based regimen. In some cases, the prior systemic therapy is a FOLFIRINOX-based regimen, and the second-line (or higher) therapy includes administration of compound G, gemcitabine, and albumin-bound paclitaxel as disclosed herein, to the patient. In some cases, the prior systemic therapy is a FOLFIRINOX-based regimen, and the second-line (or higher) therapy includes administration of compound G and mFOLFIRINOX to the patient. In some cases, the prior systemic therapy was gemcitabine and paclitaxel (e.g., albumin-bound paclitaxel), and second-line (or higher) therapy involved administering compound G, gemcitabine, and paclitaxel (e.g., albumin-bound paclitaxel) to the patient. In some cases, the prior systemic therapy was gemcitabine and cisplatin, with or without an anti-PD1 inhibitor or an anti-PDL1 (“anti-PD(L)1”) inhibitor. In some cases, the prior systemic therapy was a combination of gemcitabine and cisplatin, with or without an anti-PD(L)1 inhibitor, and second-line (or higher) therapy involved administering compound G, gemcitabine, and cisplatin to the patient.

[0046] In some embodiments, the patient has not previously been treated with liver-targeted anticancer therapies (e.g., TACE, palliative surgery) for advanced unresectable biliary cancer (intrahepatic or extrahepatic bile duct cancer or gallbladder cancer).

[0047] In some embodiments, the patient has not previously been treated with a MAT2A inhibitor (i.e., the patient is MAT2A inhibitor-naïve). A MAT2A inhibitor is a compound that inhibits methionine adenosine transferase II α. An exemplary MAT2A inhibitor is AG 270 ((3-(cyclohexyl-1-en-1-yl)-6-(4-methoxyphenyl)-2-phenyl-zetidindin-2-ylamino)pyrazolo[1,5-a]pyrimidin-7(4H)-one).

[0048] In some embodiments, the patient has not previously been treated with a PRMT5 inhibitor (i.e., the patient is PRMT5 inhibitor-naïve). A PRMT5 inhibitor is a compound that inhibits the protein arginine methyltransferase 5. The term "PRMT5 inhibitor" includes PRMT5 inhibitors that cooperate with MTA. Exemplary PRMT5 inhibitors include, but are not limited to, pemrametostat (6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinoline-2-yl)-2-hydroxypropyl]pyrimidin-4-carboxamide) and GSK3203591 (2-(cyclobutylamino)-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinoline-4-yl)). (2-hydropropyl)-4-pyridinecarboxamide dihydrochloride, LLY-283 ((R)-5′-phenyl-7-deadenylate; 6-amino-9-[(R)-5′-phenyl(furanibosyl)]-7-deadenine, (2R,3R,4S,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol), PRT 811, and MRTX1719 (2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile).

[0049] In some embodiments, the patient is not treated with compounds that are strong inducers of CYP3A4. Exemplary strong inducers of CYP3A4 include, but are not limited to, rifampin, mitotane, avasimibe, rifapentine, apalutamide, ivosidenib, phenytoin, carbamazepine, enzalutamide, St. John's wort extract, lumacaftor, and phenobarbital.

[0050] In some embodiments, the patient is not treated with compounds that are strong inhibitors of CYP3A4. Exemplary strong CYP3A4 inhibitors include, but are not limited to, VIEKIRA PAK, indinavir / ritonavir, tipranavir / ritonavir, ritonavir, cobicistat, ketoconazole, troleandomycin, telaprevir, danoprevir / ritonavir, elvitegravir / ritonavir, saquinavir / ritonavir, lopinavir / ritonavir, itraconazole, indinavir, and vortex. Riconazole, mifepristone, mibefradil, LCL161, clarithromycin, josamycin, lonafarnib, posaconazole, telithromycin, grapefruit juice, conivaptan, tucatinib, nefazodone, ceritinib, nelfinavir, saquinavir, ribociclib, idelalisib, and boceprevir.

[0051] In some embodiments, the patient does not have toxicity from previous anticancer therapies, defined as not having regressed to Grade 0 or 1 of the Common Terminology Standard for Adverse Events (CTCAE) version 5.0, or not having regressed to the level specified in the eligibility criteria, except for hair loss.

[0052] MTAP-ineffective gastrointestinal cancer

[0053] This disclosure provides a method for treating MTAP-ineffective gastrointestinal cancers in patients of need. MTAP-ineffective cancers are those lacking expression of the enzyme methionine phosphorylase (MTAP). The MTAP gene, located at chromosome 9p21, is frequently co-deleted with the CDKN2A and CDKN2B genes. Selective MTAP deficiency refers to a deficiency in the absence of CDKN2 gene co-deletion, resulting from selective deletion of the MTAP locus or methylation of the MTAP promoter. MTAP-ineffective cancers include MTAP deficiency in at least 1% of disease cells and, in some cases, at least 20% of disease cells. The terms “MTAP-ineffective,” “MTAP-deficient,” “MTAP-negative,” and “MTAP-deficient” are used interchangeably.

[0054] The terms “MTAP deficiency-associated,” “MTAP deficiency,” or “MTAP-deficient” (e.g., proliferative diseases such as cancer), “MTAP-associated” (e.g., proliferative diseases such as cancer), or “characterized by MTAP deficiency” (e.g., proliferative diseases such as cancer) refer to diseases in which a large number of cells are MTAP-deficient cells (e.g., proliferative diseases such as cancer). For example, in MTAP deficiency-associated diseases, one or more disease cells may have significantly reduced post-translational modifications, production, expression, levels, stability, and / or activity of MTAP. In patients with MTAP deficiency-associated diseases, some disease cells (e.g., cancer cells) may be MTAP-deficient cells, while others are not. Similarly, some disease cells may be MTA-accumulating cells, while others are not. Therefore, this disclosure covers treatment methods for diseases involving these tissues, or any other tissues, where the proliferation of MTAP-deficient and / or MTA-accumulating cells can be inhibited by administration of a PRMT5 inhibitor. Some MTAP-deficient cancer cells also lack CDKN2A; post-translational modifications, production, expression, level, stability, and / or activity of the CDKN2A gene or its products are attenuated in these cells. The MTAP and CDKN2A genes are very close together on chromosome 9p21; MTAP is located approximately 100 kb telomeres of CDKN2A. Many cancer cell types contain CDKN2A / MTAP loss (loss of both genes). Therefore, in some embodiments, MTAP-deficient cells also lack CDKN2A. MTAP-ineffective cancers can be identified by any suitable diagnostic test. Exemplary diagnostic tests for MTAP deficiency or loss of the MTAP protein include immunohistochemistry (IHC) and local or central next-generation sequencing (NGS).

[0055] Gastrointestinal cancers include, but are not limited to, anal cancer, appendix cancer, bile duct cancer, biliary tract cancer, colon cancer, esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumors, pancreatic islet cell tumors, liver cancer, gastrointestinal neuroendocrine tumors, pancreatic cancer, rectal cancer, and small bowel cancer. In some cases, the gastrointestinal cancer is biliary tract cancer or pancreatic cancer. In some embodiments, the MTAP-resistant gastrointestinal cancer is locally advanced. In some embodiments, the MTAP-resistant gastrointestinal cancer is metastatic.

[0056] In some embodiments, the MTAP-ineffective gastrointestinal cancer is biliary tract cancer. Biliary tract cancer, or bile duct cancer, originates from the biliary epithelium of the small ducts (intrahepatic) in the perihepatic region and the main duct at the porta hepatis (extrahepatic). Extrahepatic biliary tract cancers include gallbladder cancer, ampullary cancer, and pancreaticobiliary cancer. In some embodiments, the biliary tract cancer is locally advanced. In some cases, the biliary tract cancer is metastatic.

[0057] In some embodiments, the MTAP-resistant gastrointestinal cancer is pancreatic cancer. In some embodiments, the MTAP-resistant gastrointestinal cancer is pancreatic adenocarcinoma (e.g., pancreatic ductal adenocarcinoma (PDAC)). In some embodiments, the pancreatic ductal adenocarcinoma is locally advanced. In some embodiments, the pancreatic ductal adenocarcinoma is metastatic.

[0058] Monitoring treatment efficacy

[0059] The efficacy of a given cancer treatment can be determined by a skilled clinician. However, treatment is considered effective if, after treatment with agents as described herein, any or all signs or symptoms of the tumor, for example, show a beneficial change, or other clinically acceptable symptoms improve or even decrease by, for example, by at least 10%. Efficacy can also be measured by the stabilization or non-aggravation (i.e., cessation of disease progression) of the disease or its symptoms in an individual who is hospitalized or requires medical intervention for evaluation. Methods for measuring these indicators are known to those skilled in the art and / or described herein.

[0060] As determined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 protocol (Eisenhauer et al., 2009), a patient can respond to therapy as measured by at least stable disease (SD). RECIST v1.1 is discussed in detail in the following examples. At least stable disease is a stable disease that demonstrates a partial response (PR) or a complete response (CR) (i.e., "at least SD" = SD + PR + CR, often referred to as disease control). In various embodiments, stable disease is neither sufficiently reduced to qualify for a partial response (PR) nor sufficiently increased to qualify for progressive disease (PD). In various embodiments, the patient demonstrates at least a partial response (i.e., "at least PR" = PR + CR, often referred to as objective response). Alternatively or concurrently, patient response can be determined by the Response Assessment in Neuro-Oncology (RANO) criteria, see, for example, Chen et al., Front Oncol. [Frontiers in Oncology], 2021 11:679331.

[0061] Response can be measured by one or more of the following: reduction in tumor size, inhibition or reduction in tumor growth, reduction in target or neoplastic lesions, delay in progression time, absence of new tumors or lesions, reduction in new tumor formation, increase in survival or progression-free survival (PFS), and absence of metastasis. In various embodiments, disease progression can be assessed by measuring tumor size, neoplastic lesions, or the formation of new tumors or lesions, using computed tomography (CT) scans, positron emission tomography (PET) scans, magnetic resonance imaging (MRI) scans, X-rays, ultrasound, or combinations thereof. In some embodiments, disease progression (e.g., progression-free survival) can be assessed by measuring a reduction in ctDNA relative to baseline.

[0062] Progression-free survival (PFS) can be assessed as described in the RECIST 1.1 protocol. In various embodiments, patients exhibit at least 1 month of PFS. In various embodiments, patients exhibit at least 3 months of PFS. In some embodiments, patients exhibit at least 6 months of PFS.

[0063] Example:

[0064] 1. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient...

[0065] (a) Compound G: (G), or a pharmaceutically acceptable salt thereof;

[0066] (b) gemcitabine; and

[0067] (c) Paclitaxel.

[0068] 2. The method as described in Example 1, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0069] 3. The method as described in Example 1, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0070] 4. The method as described in any one of Examples 1-3, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0071] 5. The method as described in any one of Examples 1-3, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0072] 6. The method as described in Example 7, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0073] 7. The method as described in any one of Examples 1-6, wherein compound G is applied as a free base.

[0074] 8. The method as described in any one of Examples 1-7, wherein the method comprises administering 400 mg of compound G to the patient.

[0075] 9. The method as described in any one of Examples 1-7, wherein the method comprises administering 500 mg of compound G to the patient.

[0076] 10. The method as described in any one of Examples 1-7, wherein the method comprises administering 600 mg of compound G to the patient.

[0077] 11. The method as described in any one of Examples 1-7, wherein the method comprises administering 800 mg of compound G to the patient.

[0078] 12. The method as described in any one of Examples 1-7, wherein the method comprises administering 1200 mg of compound G to the patient.

[0079] 13. The method as described in any one of Examples 1-12, wherein compound G is administered to the patient once daily.

[0080] 14. The method as described in any one of Examples 1-13, wherein the method comprises administering 1000 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Giscitabine three times.

[0081] 15. The method as described in any one of Examples 1-14, wherein the paclitaxel is albumin-bound paclitaxel.

[0082] 16. The method as described in any one of Examples 1-15, wherein the method comprises administering 125 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Albumin-bound paclitaxel three times.

[0083] 17. The method as described in any one of Examples 1-16, wherein the method comprises administering gemcitabine and albumin-bound paclitaxel to the patient on days 1, 8, and 15 of a 28-day treatment cycle.

[0084] 18. The method of any one of Examples 1-7, the method comprising administering to the patient (a) 400 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0085] 19. The method as described in any one of Examples 1-7, the method comprising administering to the patient (a) 500 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0086] 20. The method of any one of Examples 1-7, the method comprising administering to the patient (a) 600 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0087] 21. The method as described in any one of Examples 1-7, the method comprising administering to the patient (a) 800 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0088] 22. The method as described in any one of Examples 1-7, the method comprising administering to the patient (a) 1200 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0089] 23. The method as described in any one of Examples 1-22, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

[0090] 24. The method as described in any one of Examples 1-22, wherein the patient has undergone prior systemic therapy for the MTAP-resistant gastrointestinal cancer.

[0091] 25. The method as described in Example 24, wherein the prior systemic therapy is FOLFIRINOX.

[0092] 26. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient...

[0093] (a) Compound G: or its pharmaceutically acceptable salt; and

[0094] (b)(i) A combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin, and (iv) oxaliplatin.

[0095] 27. The method as described in Example 26, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0096] 28. The method as described in Example 26, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0097] 29. The method as described in any one of Examples 26-28, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0098] 30. The method as described in any one of Examples 26-28, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0099] 31. The method as described in Example 30, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0100] 32. The method as described in any one of Examples 26-31, wherein compound G is applied as a free base.

[0101] 33. The method as described in any one of Examples 26-32, wherein the method comprises administering 400 mg of compound G to the patient.

[0102] 34. The method as described in any one of Examples 26-32, wherein the method comprises administering 500 mg of compound G to the patient.

[0103] 35. The method as described in any one of Examples 26-32, wherein the method comprises administering 600 mg of compound G to the patient.

[0104] 36. The method as described in any one of Examples 26-32, wherein the method comprises administering 800 mg of compound G to the patient.

[0105] 37. The method of any one of Examples 26-32, wherein the method comprises administering 1200 mg of compound G to the patient.

[0106] 38. The method as described in any one of Examples 26-37, wherein compound G is administered to the patient once daily.

[0107] 39. The method as described in any one of Examples 26-38, wherein the method comprises administering 150 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Irinotecan twice.

[0108] 40. The method as described in any one of Examples 26-39, wherein the method comprises administering 2400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 5-Fluorouracil twice.

[0109] 41. The method as described in any one of Examples 26-40, wherein the method comprises administering 400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Two doses of folinic acid.

[0110] 42. The method as described in any one of Examples 26-41, wherein the method comprises administering 85 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Oxaliplatin twice.

[0111] 43. The method as described in any one of Examples 26-42, wherein the irinotecan, 5-fluorouracil, leucovorin and oxaliplatin are administered on day 1 and day 15 of a 28-day treatment cycle.

[0112] 44. The method as described in any one of Examples 26-32, 38 and 43, the method comprising administering to the patient (a) 400 mg of compound G once daily, (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0113] 45. The method as described in any one of Examples 26-32, 38 and 43, the method comprising administering to the patient (a) 500 mg of compound G once daily, (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0114] 46. ​​The method as described in any one of Examples 26-32, 38 and 43, the method comprising administering to the patient (a) 600 mg of compound G once daily, (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0115] 47. The method as described in any one of Examples 26-32, 38 and 43, the method comprising administering to the patient (a) 800 mg of compound G once daily, (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0116] 48. The method as described in any one of Examples 26-32, 38 and 43, the method comprising administering to the patient (a) 1200 mg of compound G once daily, (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0117] 49. The method as described in any one of Examples 26-48, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

[0118] Another embodiment:

[0119] 1A. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient...

[0120] (a) Compound G: or its pharmaceutically acceptable salt;

[0121] (b) Gescitabine;

[0122] (c) Cisplatin; and

[0123] (d) Anti-PD1 antibody or anti-PDL1 antibody.

[0124] 2A. The method as described in Example 1A, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0125] 3A. The method as described in Example 1A, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0126] 4A. The method as described in any one of Examples 1A-3A, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0127] 5A. The method as described in any one of Examples 1A-3A, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0128] 6A. The method as described in Example 5A, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0129] 7A. The method as described in Example 1A, wherein compound G is applied as a free base.

[0130] 8A. The method as described in any one of Examples 1A-7A, wherein compound G is administered once daily.

[0131] 9A. The method as described in any one of Examples 1A-8A, wherein the method comprises administering 400 mg of compound G to the patient.

[0132] 10A. The method as described in any one of Examples 1A-8A, wherein the method comprises administering 500 mg of compound G to the patient.

[0133] 11A. The method as described in any one of Examples 1A-8A, wherein the method comprises administering 600 mg of compound G to the patient.

[0134] 12A. The method as described in any one of Examples 1-8, wherein the method comprises administering 800 mg of compound G to the patient.

[0135] 13A. The method as described in any one of Examples 1A-8A, wherein the method comprises administering 1200 mg of compound G to the patient.

[0136] 14A. The method as described in any one of Examples 1A-13A, wherein the anti-PDL1 antibody is administered to the patient.

[0137] 15A. The method as described in any one of Examples 1A-13A, wherein the anti-PD1 antibody is administered to the patient.

[0138] 16A. The method as described in Example 15A, wherein the anti-PD1 antibody is pembrolizumab.

[0139] 17A. The method as described in Example 16A, wherein the method comprises administering 200 mg of pembrolizumab once via IV to the patient during a 21-day treatment cycle.

[0140] 18A. The method as described in any one of Examples 1-17A, wherein the method comprises administering 1000 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Giscitabine.

[0141] 19A. The method as described in any one of Examples 1-18A, wherein the method comprises administering 25 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Cisplatin.

[0142] 20A. The method as described in any one of Examples 1A-8A, the method comprising administering to the patient (a) 400 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and in a 21-day treatment cycle, pembrolizumab is administered once via IV.

[0143] 21A. The method as described in any one of Examples 1A-8A, the method comprising administering to the patient (a) 500 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m².2 Gemcitabine and 25 mg / m 2 Cisplatin, and in a 21-day treatment cycle, pembrolizumab is administered once via IV.

[0144] 22A. The method as described in any one of Examples 1A-8A, the method comprising administering to the patient (a) 600 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and in a 21-day treatment cycle, pembrolizumab is administered once via IV.

[0145] 23A. The method as described in any one of Examples 1A-8A, the method comprising administering to the patient (a) 800 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and in a 21-day treatment cycle, pembrolizumab is administered once via IV.

[0146] 24A. The method as described in any one of Examples 1A-8A, the method comprising administering to the patient (a) 1200 mg of compound G once daily, (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and in a 21-day treatment cycle, pembrolizumab is administered once via IV.

[0147] Another embodiment:

[0148] 1B. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective amount of each of the following:

[0149] (a) Compound G: (G), or a pharmaceutically acceptable salt thereof;

[0150] (b) gemcitabine; and

[0151] (c) Paclitaxel.

[0152] 2B. The method as described in Example 1B, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0153] 3B. The method as described in Example 1B, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0154] 4B. The method as described in any one of Examples 1B-3B, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0155] 5B. The method as described in any one of Examples 1B-3B, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0156] 6B. The method as described in Example 7B, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0157] 7B. The method as described in any one of Examples 1B-6B, wherein compound G is applied as a free base.

[0158] 8B. The method as described in any one of Examples 1B-7B, wherein the method comprises administering to the patient a total daily dose of 500 mg of compound G or a salt thereof, based on the free base weight of compound G.

[0159] 9B. The method as described in any one of Examples 1B-7B, wherein the method comprises administering to the patient a total daily dose of 600 mg of compound G or a salt thereof, based on the free base weight of compound G.

[0160] 10B. The method as described in any one of Examples 1B-7B, wherein the method comprises administering to the patient a total daily dose of 800 mg of compound G or a salt thereof, based on the free base weight of compound G.

[0161] 11B. The method as described in any one of Examples 1B-7B, wherein the method comprises administering to the patient a total daily dose of 900 mg of compound G or a salt thereof, based on the free base weight of compound G.

[0162] 12B. The method as described in any one of Examples 1B-7B, wherein the method comprises administering to the patient a total daily dose of 1200 mg of compound G or a salt thereof, based on the free base weight of compound G.

[0163] 13B. The method as described in any one of Examples 1B-12B, wherein compound G is administered to the patient once daily.

[0164] 14B. The method as described in any one of Examples 1B-13B, wherein compound G is administered orally.

[0165] 15B. The method as described in any one of Examples 1B-14B, wherein compound G is administered as a tablet formulation.

[0166] 16B. The method as described in any one of Examples 1B-15B, wherein the method comprises administering 1000 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Giscitabine three times.

[0167] 17B. The method as described in any one of Examples 1B-16B, wherein the paclitaxel is an albumin-bound paclitaxel.

[0168] 18B. The method as described in any one of Examples 1B-17B, wherein the method comprises administering 125 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Albumin-bound paclitaxel three times.

[0169] 19B. The method as described in any one of Examples 1B-18B, wherein the method comprises administering gemcitabine and albumin-bound paclitaxel to the patient on days 1, 8, and 15 of a 28-day treatment cycle.

[0170] 20B. The method as described in any one of Examples 1B-7B and 13B-15B, comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0171] 21B. The method as described in any one of Examples 1B-7B and 13B-15B, comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m² 2 Gemcitabine and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0172] 22B. The method as described in any one of Examples 1B-7B and 13B-15B, comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0173] 23B. The method as described in any one of Examples 1B-7B and 13B-15B, comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0174] 24B. The method as described in any one of Examples 1B-7B and 13B-15B, comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m 2 Gemcitabine and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

[0175] 25B. The method as described in any one of Examples 1B-24B, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

[0176] 26B. The method as described in any one of Examples 1B-24B, wherein the patient has undergone prior systemic therapy for the MTAP-resistant gastrointestinal cancer.

[0177] 27B. The method as described in Example 26B, wherein the prior systemic therapy is FOLFIRINOX.

[0178] 28B. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective amount of each of the following:

[0179] (a) Compound G: or its pharmaceutically acceptable salt; and

[0180] (b)(i) A combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin, and (iv) oxaliplatin.

[0181] 29B. The method as described in Example 28B, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0182] 30B. The method as described in Example 28B, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0183] 31B. The method as described in any one of Examples 28B-30B, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0184] 32B. The method as described in any one of Examples 30B-32B, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0185] 33B. The method as described in Example 32B, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0186] 34B. The method as described in any one of Examples 28B-33B, wherein compound G is applied as a free base.

[0187] 35B. The method as described in any one of Examples 28B-34B, wherein the method comprises administering 500 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0188] 36B. The method as described in any one of Examples 28B-34B, wherein the method comprises administering 600 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0189] 37B. The method as described in any one of Examples 28B-34B, wherein the method comprises administering 800 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0190] 38B. The method as described in any one of Examples 28B-34B, wherein the method comprises administering 900 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0191] 39B. The method as described in any one of Examples 28B-34B, wherein the method comprises administering 1200 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0192] 40B. The method as described in any one of Examples 28B-39B, wherein compound G is administered to the patient once daily.

[0193] 41B. The method as described in any one of Examples 28B-40B, wherein compound G is administered orally.

[0194] 42B. The method as described in any one of Examples 28B-41B, wherein compound G is administered as a tablet formulation.

[0195] 43B. The method as described in any one of Examples 28B-42B, wherein the method comprises administering 150 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Irinotecan twice.

[0196] 44B. The method as described in any one of Examples 28B-43B, wherein the method comprises administering 2400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 5-Fluorouracil twice.

[0197] 45B. The method as described in any one of Examples 28B-44B, wherein the method comprises administering 400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Two doses of folinic acid.

[0198] 46B. The method as described in any one of Examples 28B-45B, wherein the method comprises administering 85 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Oxaliplatin twice.

[0199] 47B. The method as described in any one of Examples 28B-46B, wherein the irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin are administered on days 1 and 15 of a 28-day treatment cycle.

[0200] 48B. The method as described in any one of Examples 28B-33B and 40B-42B, comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0201] 49B. The method as described in any one of Examples 28B-33B and 40B-42B, comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0202] 50B. The method as described in any one of Examples 28B-33B and 40B-42B, comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0203] 51B. The method as described in any one of Examples 28B-33B and 40B-42B, comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0204] 52B. The method as described in any one of Examples 28B-33B and 40B-42B, comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid and (iv) 85 mg / m 2 The combination of oxaliplatin, with the 150 mg / m² administered on days 1 and 15 of a 28-day treatment cycle. 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin.

[0205] 53B. The method as described in any one of Examples 48B-52B, wherein compound G is applied as a free base.

[0206] 54B. The method as described in any one of Examples 28B-53B, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

[0207] 55B. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective amount of each of the following:

[0208] (a) Compound G: or its pharmaceutically acceptable salt;

[0209] (b) Gescitabine;

[0210] (c) Cisplatin; and

[0211] (d) Anti-PD1 antibody or anti-PDL1 antibody.

[0212] 56B. The method as described in Example 55B, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

[0213] 57B. The method as described in Example 55B, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

[0214] 58B. The method as described in any one of Examples 55B-57B, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

[0215] 59B. The method as described in any one of Examples 55B-57B, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

[0216] 60B. The method as described in Example 59B, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

[0217] 61B. The method as described in any one of Examples 55B-60B, wherein the method comprises administering 500 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0218] 62B. The method as described in any one of Examples 55B-60B, wherein the method comprises administering 600 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0219] 63B. The method as described in any one of Examples 55B-60B, wherein the method comprises administering 800 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0220] 64B. The method as described in any one of Examples 55B-60B, wherein the method comprises administering 900 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0221] 65B. The method as described in any one of Examples 55B-60B, comprising administering 1200 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

[0222] 66B. The method as described in any one of Examples 55B-65B, wherein compound G is applied as a free base.

[0223] 67B. The method as described in any one of Examples 55B-66B, wherein compound G is administered once daily.

[0224] 68B. The method as described in any one of Examples 55B-67B, wherein compound G is administered orally.

[0225] 69B. The method as described in any one of Examples 55B-68B, wherein compound G is administered as a tablet formulation.

[0226] 70B. The method as described in any one of Examples 55B-69B, wherein the anti-PDL1 antibody is administered to the patient.

[0227] 71B. The method as described in any one of Examples 55B-69B, wherein the anti-PD1 antibody is administered to the patient.

[0228] 72B. The method as described in Example 71B, wherein the anti-PD1 antibody is pembrolizumab.

[0229] 73B. The method as described in Example 72B, wherein the method comprises administering 200 mg of pembrolizumab once via IV to the patient during a 21-day treatment cycle.

[0230] 74B. The method as described in any one of Examples 55B-73B, wherein the method comprises administering 1000 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Giscitabine.

[0231] 75B. The method as described in any one of Examples 55B-74B, wherein the method comprises administering 25 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Cisplatin.

[0232] 76B. The method as described in any one of Examples 55B-60B and 67B-69B, comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin and (d) 200 mg pembrolizumab, wherein the 1000 mg / m² dose is administered intravenously on days 1 and 8 of each 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

[0233] 77B. The method as described in any one of Examples 55B-60B and 67B-69B, comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin and (d) 200 mg pembrolizumab, wherein the 1000 mg / m² dose is administered intravenously on days 1 and 8 of each 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

[0234] 78B. The method as described in any one of Examples 55B-60B and 67B-69B, comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin and (d) 200 mg pembrolizumab, wherein the 1000 mg / m² dose is administered intravenously on days 1 and 8 of each 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

[0235] 79B. The method as described in any one of Examples 55B-60B and 67B-69B, comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G; (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin and (d) 200 mg pembrolizumab, wherein the 1000 mg / m² dose is administered intravenously on days 1 and 8 of each 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

[0236] 80B. The method as described in any one of Examples 55B-60B and 67B-69B, comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m 2 Gemcitabine, (c) 25 mg / m 2Cisplatin and (d) 200 mg pembrolizumab, wherein the 1000 mg / m² dose is administered intravenously on days 1 and 8 of each 21-day treatment cycle. 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

[0237] Example

[0238] Example 1

[0239] This is a phase 1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of compound G in combination with gemcitabine and albumin-bound paclitaxel or in combination with mFOLFIRINOX in subjects with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deficiency.

[0240] This study consisted of two treatment groups: Group A and Group B. Group A assessed the safety of compound G in combination with gemcitabine and albumin-bound paclitaxel. Group B assessed the safety of compound G in combination with mFOLFIRINOX (irinotecan, 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin). Gemcitabine and albumin-bound paclitaxel (in Group A) and mFOLFIRINOX (in Group B) were administered at standard doses (see Treatment section below). The following dose levels of compound G were explored in Groups A and B:

[0241] Dosage level 2: 1200 mg once daily (QD)

[0242] Dosage level 1: 800 mg once daily (QD)

[0243] Dosage level - 1,500 mg once daily (QD)

[0244] Groups A and B will start at dose level 1.

[0245] Summary of subject eligibility criteria:

[0246] Adult subjects (≥ 18 years) with homozygous MTAP loss in advanced PDAC, assessed by local or central next-generation sequencing (NGS) testing, and with an ECOG performance status of 0 or 1, will be eligible to participate in the study. MTAP loss confirmed by local immunohistochemistry is also acceptable. MTAP loss status can be determined during pre-screening testing. Once consent is given, subjects will provide their medical history and undergo screening safety tests to confirm they meet all study eligibility requirements. Subjects must have adequate blood, kidney, and liver function. Subjects must provide archived tumor tissue samples (formalin-fixed, paraffin-embedded [FFPE] samples) collected within the past 5 years. If archived tumor tissue is unavailable, subjects must be willing to undergo a tumor biopsy prior to treatment, provided the investigator deems it safe.

[0247] treat

[0248] Group A and Group B: Compound G was administered once daily for 28 consecutive days.

[0249] Group A: Gemcitabine in combination with albumin-bound paclitaxel, administered intravenously (IV) on days 1, 8, and 15 of each 28-day cycle (gemcitabine: 1000 mg / m²). 2 ; and albumin-bound paclitaxel: 125 mg / m² 2 ).

[0250] Group B: mFOLFIRINOX, administered intravenously (IV) on days 1 and 15 of each 28-day cycle.

[0251] -Irinotecan (150 mg / m²) 2 )

[0252] -5-FU (2400 mg / m²) 2 (After 46 to 48 hours)

[0253] -Folic acid (400 mg / m 2 ),and

[0254] -Oxaliplatin (85 mg / m²) 2 )

[0255] Exemplary inclusion criteria

[0256] - Age ≥ 18 years old (or ≥ the legal age in China if the legal age in China is greater than 18 years old).

[0257] - A histologically or cytologically confirmed diagnosis of metastatic and / or unresectable (locally advanced) pancreatic adenocarcinoma, and no prior systemic therapy for metastatic or unresectable disease other than the 28-day first-line therapy outlined in the exemplary exclusion criteria below.

[0258] Exemplary exclusion criteria

[0259] Prior concomitant therapy:

[0260] - Prior systemic therapy for advanced (metastatic) or unresectable (locally advanced) pancreatic adenocarcinoma. Eligible subjects are those who have started first-line standard-of-care therapy (i.e., gemcitabine and albumin-bound paclitaxel (Group A) or mFOLFIRINOX (Group B)) and are within 28 days of their first dose at the time of signing the primary informed consent form, in order to be able to perform local or central pre-screening NGS testing to determine MTAP absence. (Exceptions: Group A: Prior FOLFIRINOX-based regimens are permitted regardless of duration. Group B: Prior gemcitabine / albumin-bound paclitaxel-based regimens are permitted regardless of duration.)

[0261] Neoadjuvant / Adjuvant Therapy

[0262] - Dosage exploration: Allows for unconditional administration of previous neoadjuvant / adjuvant therapies.

[0263] - Prior neoadjuvant / adjuvant therapy is permitted if the diagnosis was completed at least 6 months prior to advanced and / or unresectable disease, and if the subject has not received gemcitabine and / or albumin-bound paclitaxel (Group A) or any active agent of FOLFIRINOX (Group B) in a neoadjuvant / adjuvant setting. Participants who have received prior neoadjuvant / adjuvant therapy and whose post-tumor resection pathology is R2 are excluded. Note: Bisphosphonates or denosumab are permitted for use in skeletal-related events, according to institutional guidelines.

[0264] - Perform major surgery within 28 days of the first dose of the study treatment. Note: Surgery is permitted to obtain a biopsy for diagnostic purposes.

[0265] -Previously treated with MAT2A inhibitors or PRMT5 inhibitors.

[0266] - Toxicity caused by previous antitumor therapy has not improved to at least Grade 1 of the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, except for alopecia or stable and well-controlled toxicity.

[0267] -Previous irradiation > 25% of bone marrow.

[0268] - Receive radiation therapy within 28 days of the first dose (or local or focused radiation therapy for palliative purposes within 14 days of the first dose). A lesion is considered measurable if it has progressed in one or more previously treated lesions and meets the criteria for measurable disease according to RECIST 1.1.

[0269] - All radiation therapy-related toxicities must improve to grade ≤ 1 before the first dose of the study treatment.

[0270] - Live vaccine therapy was administered within 4 weeks prior to the study drug administration.

[0271] - If a prescription drug known as a strong inducer or inhibitor of CYP3A4 was used within 14 days or 5 half-lives (whichever is longer) prior to Day 1 of the study.

[0272] - It has known sensitivity to any component of the treatment under investigation.

[0273] Related diseases

[0274] - Untreated CNS metastatic disease, regardless of symptoms. Subjects with treated CNS metastases who have maintained radiographic and neurological stability for ≥ 28 days prior to the first dose of study treatment, do not require corticosteroids for at least 14 days, and do not require antiepileptic prophylaxis or treatment are eligible.

[0275] - Subjects with leptomeningeal disease were excluded regardless of whether symptoms were present or not, even after treatment.

[0276] Patients with pleural effusion or ascites need therapeutic drainage (such as thoracentesis or paracentesis) more than once a month.

[0277] Other medical conditions

[0278] A history of other malignancies within the past 3 years prior to the first dose, except for: (1) carcinoma in situ and precancerous lesions adequately treated without evidence of disease; (2) malignancies treated for curative purposes and without known active disease for ≥ 2 years prior to the first dose (excluding carcinoma in situ), and for which the treating physician considers the risk of recurrence to be low. Note: Patients with prior or concurrent malignancies may qualify if the investigator considers the risk of malignancy interfering with safety or efficacy endpoints to be very low.

[0279] - Evidence of interstitial lung disease or active, non-infectious pneumonia or uncontrolled asthma.

[0280] - A confirmed medical history requiring immunosuppressive therapy or a current autoimmune disease.

[0281] - A history of diseases that lead to permanent immunosuppression.

[0282] - Active infection requiring systemic therapy. Subjects must have symptoms and / or clinical and / or imaging signs within 14 days of administration that indicate an acute and / or uncontrolled active fungal, bacterial, viral, or other infection requiring anti-infective therapy. Note: Uncomplicated urinary tract infections and uncomplicated bacterial pharyngitis are permissible if there is a response to aggressive treatment and after consultation with a medical monitor. Screening for chronic infectious conditions is not required unless otherwise stated in the eligibility criteria.

[0283] - History of arterial or untreated venous thrombosis: (1) Arterial thrombosis within 12 months of the first dose (e.g., stroke, transient ischemic attack); (2) Untreated venous thromboembolism (e.g., DVT, pulmonary embolism). Subjects who have received stable anticoagulation therapy for ≥ 1 month prior to the first dose are eligible.

[0284] - Myocardial infarction and / or symptomatic congestive heart failure (New York Heart Association class II), unstable angina, or cardiac arrest, ventricular tachycardia, a known history of Wolf-Parkinson-White syndrome, or a genetic syndrome that increases the risk of sudden cardiac death (e.g., long QT syndrome, short QT syndrome, hereditary hypertrophic cardiomyopathy, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, or catecholamine polymorphic ventricular tachycardia).

[0285] - Gastrointestinal disorders that prevent the use of PO medications, malabsorption syndrome (excluding compensatory pancreatic exocrine insufficiency for sufficient pancreatic enzymes), the need for IV high-energy nutrition, feeding via gastric tube / jejunal tube, and uncontrolled inflammatory gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis).

[0286] - A history of intestinal obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of the first dose of compound G.

[0287] - A history or evidence of a gastrointestinal disorder (defined as CTCAE grade ≥ 2) that causes chronic nausea, vomiting, or diarrhea.

[0288] - Grade 2 or higher peripheral neuropathy.

[0289] - History of solid organ transplantation.

[0290] - Diagnosis of congenital short QT syndrome.

[0291] - Group B only: History of known complete deficiency of dihydropyrimidine dehydrogenase (DPD).

[0292] -Group B only: homozygous UGT1A1 6 or UGT1A1 28 or complex hybrid UGT1A1 6 and UGT1A1 28 known UGT gene polymorphisms.

[0293] - Group B only: Diagnosis of congenital long QT syndrome and / or QTc interval > 470 ms (female) and > 450 ms (male).

[0294] Previous / companion therapy

[0295] - Currently receiving treatment in another research facility or drug study, or less than 21 days or 5 half-lives (whichever is shorter) after completing treatment in another research facility or one or more drug studies. This excludes cases where other research procedures or observational studies are being conducted concurrently with this study.

[0296] - Group B only: Use of prescription medications known to prolong the QT interval, including Class Ia and III antiarrhythmic drugs. Exceptions: Antiemetics such as ondansetron are permitted for periodic QT interval monitoring in the study.

[0297] Diagnostic assessment

[0298] - A known positive human immunodeficiency virus (HIV) test, in which a viral load is detectable and no appropriate treatment is available. Note: Eligible subjects are those adequately managed with a therapy that does not interact with any therapy in the study treatment or interfere with full-dose treatment.

[0299] - Viral hepatitis infection based on the following results and / or criteria: (1) Positive hepatitis B surface antigen (HBsAg). (2) If HBsAg is negative and hepatitis B core antibody is positive, then: polymerase chain reaction of hepatitis B virus DNA is required. Subjects with detectable hepatitis B virus DNA are ineligible.

[0300] - If hepatitis C virus antibody (HCVAb) is positive: PCR for hepatitis C virus RNA is required. Subjects who test positive for hepatitis C virus RNA are ineligible.

[0301] Preliminary data (data as of February 6, 2025)

[0302]

[0303] Example 2

[0304] This is a phase 1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of compound G in combination with gemcitabine, cisplatin, and pembrolizumab in subjects with homozygous MTAP-deficient (“MTAP-ineffective”) biliary tract cancer (BTC).

[0305] The following dose levels of compound G were investigated:

[0306] Dosage level 2: 1200 mg once daily (QD)

[0307] Dosage level 1: 800 mg once daily (QD)

[0308] Dosage level-1: 500 mg once daily (QD)

[0309] The study began at dose level 1.

[0310] Summary of subject eligibility criteria:

[0311] Adult subjects (≥ 18 years) with homozygous MTAP loss in advanced BTC, assessed by local or central next-generation sequencing (NGS) testing, are eligible to participate in the study. MTAP loss confirmed by local immunohistochemistry is also acceptable. MTAP loss can be determined in pre-screening assays. Once consent is given, subjects will provide their medical history and undergo screening safety tests to confirm they meet all study eligibility requirements. Subjects must have adequate blood, kidney, and liver function. Subjects must provide archived tumor tissue samples (formalin-fixed, paraffin-embedded [FFPE] samples) collected within the past 5 years. If archived tumor tissue is unavailable, subjects must be willing to undergo a tumor biopsy prior to treatment, provided the investigator deems it safe.

[0312] treat

[0313] Compound G was administered once daily for 21 consecutive days.

[0314] Gemcitabine in combination with cisplatin was administered intravenously (IV) on days 1 and 8 of each 21-day treatment cycle (gemcitabine: 1000 mg / m²). 2 ; and cisplatin: 25 mg / m 2 (Maximum 8 cycles).

[0315] Pembrolizumab (200 mg) is administered on day 1 of each 21-day treatment cycle (up to 35 cycles).

[0316] Exemplary exclusion criteria

[0317] Prior concomitant therapy:

[0318] - Prior systemic therapy for advanced (metastatic) or unresectable (locally advanced) biliary tract cancer (intrahepatic or extrahepatic bile duct cancer or gallbladder cancer). Eligible subjects were those who had started first-line standard-of-care therapy (i.e., gemcitabine and cisplatin, with or without an anti-PD(L)1 inhibitor) and were within 28 days of their first dose when signing the primary informed consent form, in order to be able to perform local or central pre-screening NGS testing to determine MTAP deficiency.

[0319] -Neoadjuvant / adjuvant therapies:

[0320] - Dosage exploration: Allows for unconditional administration of previous neoadjuvant / adjuvant therapies.

[0321] - Dosage extension: Prior neoadjuvant / adjuvant therapy is permitted if completed at least 6 months prior to diagnosis of advanced and / or unresectable disease, and if the subject has not received gemcitabine and / or cisplatin and / or anti-PD(L)1 antibody in a neoadjuvant / adjuvant setting. Participants who have received prior neoadjuvant / adjuvant therapy and have a post-tumor resection pathology of R2 are excluded. Note: Bisphosphonates or denosumab are permitted for use in skeletal-related events, as per institutional guidelines.

[0322] - Perform major surgery within 28 days of the first dose of compound G.

[0323] - Previous liver-directed anticancer therapies (e.g., TACE, palliative surgery) for advanced unresectable biliary tract cancer (intrahepatic or extrahepatic bile duct cancer or gallbladder cancer), including study agents administered within 4 weeks prior to the first dose of the study treatment.

[0324] -Previously treated with MAT2A inhibitors or PRMT5 inhibitors.

[0325] - Toxicity caused by previous antitumor therapy has not improved to at least Grade 1 of the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, except for alopecia or stable and well-controlled toxicity.

[0326] - Subjects who have experienced a grade 2 or higher immune-mediated adverse event (irAE), including those who have permanently discontinued immuno-oncology drugs (for immune agonists, including TCEs). The following is excluded: endocrine disorders treated with alternative therapy.

[0327] -Previous irradiation > 25% of bone marrow.

[0328] - Receive radiation therapy within 28 days of the first dose (or local or focused radiation therapy for palliative purposes within 14 days of the first dose). All radiation therapy-related toxicities must improve to ≤ Grade 1 before the first dose of the study treatment.

[0329] - Live vaccine therapy was administered within 4 weeks prior to the study drug administration.

[0330] - Use of prescription drugs that are known strong inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives (whichever is longer) prior to Day 1 of the study without review and approval by the principal investigator and medical monitor.

[0331] - It has known sensitivity to any component of the treatment under investigation.

[0332] Related diseases

[0333] - Untreated CNS metastatic disease, regardless of symptoms. Subjects with treated CNS metastases who have maintained radiographic and neurological stability for ≥ 28 days prior to the first dose of study treatment, do not require corticosteroids for at least 14 days, and do not require antiepileptic prophylaxis or treatment are eligible.

[0334] - Subjects with leptomeningeal disease were excluded regardless of whether symptoms were present or not, even after treatment.

[0335] - Ampullary cancer.

[0336] Patients with pleural effusion or ascites need therapeutic drainage (such as thoracentesis or paracentesis) more than once a month.

[0337] Other medical conditions

[0338] - A history of other malignancies within the past 3 years, except for: (1) carcinoma in situ and precancerous lesions that have been adequately treated without evidence of disease; (2) malignancies (excluding carcinoma in situ) that have been treated for curative purposes and have no known active disease for ≥ 2 years prior to the first dose, and whose treating physician considers the risk of recurrence to be low. Note: Patients with prior or concurrent malignancies may qualify if the investigator considers the risk of malignancy interfering with safety or efficacy endpoints to be very low.

[0339] - Evidence of interstitial lung disease or active, non-infectious pneumonia or uncontrolled asthma.

[0340] - A confirmed medical history requiring immunosuppressive therapy or a current autoimmune disease.

[0341] - A history of diseases that lead to permanent immunosuppression.

[0342] - Active infection requiring systemic therapy. Subjects must have symptoms and / or clinical and / or imaging signs within 14 days of administration that indicate an acute and / or uncontrolled active fungal, bacterial, viral, or other infection requiring anti-infective therapy. Note: Uncomplicated urinary tract infections and uncomplicated bacterial pharyngitis are permissible if there is a response to aggressive treatment and after consultation with a medical monitor. Screening for chronic infectious conditions is not required unless otherwise stated in the eligibility criteria.

[0343] - History of arterial or venous thrombosis: (1) Arterial thrombosis within 12 months of the first dose (e.g., stroke, transient ischemic attack). (2) Untreated venous thromboembolism (e.g., DVT, pulmonary embolism). Subjects who have received stable anticoagulation therapy for ≥ 1 month prior to the first dose are eligible.

[0344] - Patients who have experienced myocardial infarction and / or symptomatic congestive heart failure (New York Heart Association Class II), unstable angina, or arrhythmias requiring medical treatment within 6 months of the first dose of compound G. Patients requiring therapy must have been on a stable regimen for at least 6 months.

[0345] - Gastrointestinal diseases that cannot be treated with PO drugs, malabsorption syndrome, requiring IV high-energy nutrition, feeding via gastric tube / jejunal tube, and uncontrolled inflammatory gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis).

[0346] - A history or evidence of a gastrointestinal disorder (defined as CTCAE grade ≥ 2) that causes chronic nausea, vomiting, or diarrhea.

[0347] - Grade 2 or higher peripheral neuropathy.

[0348] - History of solid organ transplantation.

[0349] - Diagnosis of congenital short QT syndrome.

[0350] Previous / companion therapy

[0351] - Currently receiving treatment in another research facility or drug study, or less than 21 days or 5 half-lives after completing treatment in another research facility or one or more drug studies. This excludes concurrent participation in other research procedures or observational studies. Participation in observational studies should be discussed with a medical monitor.

[0352] Diagnostic assessment

[0353] - A known positive test for human immunodeficiency virus (HIV), in which viral load is detectable and there is no appropriate treatment.

[0354] - Viral hepatitis infection based on the following results and / or criteria:

[0355] - Hepatitis B surface antigen (HBsAg) is positive.

[0356] - HBsAg negative and hepatitis B core antibody positive:

[0357] - A polymerase chain reaction (PCR) is required to detect hepatitis B virus DNA. Subjects who test positive for hepatitis B virus DNA are ineligible.

[0358] - Positive hepatitis C virus antibody (HCVAb): PCR testing for hepatitis C virus RNA is required. Subjects testing positive for hepatitis C virus RNA are ineligible.

[0359] References:

[0360] ABRAXANE® US Prescribing Information, Bristol-Myers Squibb Company, New Jersey, 08543 (revision 8 / 2020).

[0361] CALCIUM FOLINATE (Leucovorin Calcium) US Prescribing Information, Bedford Laboratories, Bedford, OH 44146 (revision 11 / 2011).

[0362] CAMPTOSTAR® (irinotecan), US Prescribing Information, Pfizer, Inc, New York, NY 10017 (revision 12 / 2014).

[0363] Chen et al., Front Oncol., 2021 11:679331.

[0364] Eisenhauer, et al., Eur. J. Cancer 2009 45:228-247.

[0365] ELOXATIN® (oxaliplatin), US Prescribing Information, Pfizer, NewYork 1017 (revision 4 / 2016).

[0366] FLUOROURACIL, US Prescribing Information, Fresenius Kabi, LakeZurich, IL 60047 (revision 2 / 2024).

[0367] GEMZAR® US Prescribing Information, Eli Lily & Co., Indianapolis, IN46285 (revision 5 / 2019).

[0368] KEYTRUDA® US Prescribing Information, Merck & Co., Kenilworth, NJ07033 (revision 1 / 2025).

[0369] KHAPZORY® US Prescribing Information, Spectrum Pharmaceuticals,Inc., Irvine, CA 92618 (revision 10-2018).

[0370] LIBTAYO® US Prescribing Information, Regeneron Pharmaceuticals,Inc., Tarrytown, NY 10591 (revision 4 / 2024).

[0371] National Cancer Institute Common Terminology Criteria for AdverseEvents v5.0 (NCI CTCAE) published Nov. 27, 2017 by the National CancerInstitute.

[0372] OPDIVO® US Prescribing Information, Bristol-Myers Squibb Co.,Princeton, NJ 08543 (revision 10 / 2024).

[0373] PLATINOL® US Prescribing Information, Bristol-Myers Squibb Co.,Princeton, NJ 08543 (revision 12 / 2023).

[0374] TAXOL® (paclitaxel) INJECTION U.S. Prescribing Information, Bristol-Myers Squibb Company, Princeton, New Jersey, 08543 (revision 4 / 2011).

Claims

1. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective dose of each of the following: (a) Compound G: (G), or a pharmaceutically acceptable salt thereof; (b) gemcitabine; and (c) Paclitaxel.

2. The method of claim 1, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

3. The method of claim 1, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

4. The method according to any one of claims 1-3, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

5. The method according to any one of claims 1-3, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

6. The method of claim 7, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

7. The method according to any one of claims 1-6, wherein compound G is applied as a free base.

8. The method of any one of claims 1-7, the method comprising administering to the patient a total daily dose of 500 mg of compound G or a salt thereof, based on the free base weight of compound G.

9. The method of any one of claims 1-7, the method comprising administering to the patient a total daily dose of 600 mg of compound G or a salt thereof, based on the free base weight of compound G.

10. The method of any one of claims 1-7, wherein the method comprises administering to the patient a total daily dose of 800 mg of compound G or a salt thereof, based on the free base weight of compound G.

11. The method of any one of claims 1-7, the method comprising administering to the patient a total daily dose of 900 mg of compound G or a salt thereof, based on the free base weight of compound G.

12. The method of any one of claims 1-7, wherein the method comprises administering to the patient a total daily dose of 1200 mg of compound G or a salt thereof, based on the free base weight of compound G.

13. The method of any one of claims 1-12, wherein compound G is administered to the patient once daily.

14. The method of any one of claims 1-13, wherein compound G is administered orally.

15. The method of any one of claims 1-14, wherein compound G is administered as a tablet formulation.

16. The method of any one of claims 1-15, wherein the method comprises administering 1000 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Giscitabine three times.

17. The method of any one of claims 1-16, wherein the paclitaxel is albumin-bound paclitaxel.

18. The method of any one of claims 1-17, wherein the method comprises administering 125 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Albumin-bound paclitaxel three times.

19. The method of any one of claims 1-18, wherein the method comprises administering gemcitabine and albumin-bound paclitaxel to the patient on days 1, 8, and 15 of a 28-day treatment cycle.

20. The method of any one of claims 1-7 and 13-15, the method comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, or (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

21. The method according to any one of claims 1-7 and 13-15, the method comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

22. The method of any one of claims 1-7 and 13-15, the method comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

23. The method of any one of claims 1-7 and 13-15, the method comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

24. The method according to any one of claims 1-7 and 13-15, the method comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, and (c) 125 mg / m 2 Albumin-bound paclitaxel, of which 1000 mg / m² 2 Gemcitabine and 125 mg / m 2 Albumin-bound paclitaxel was administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle.

25. The method of any one of claims 1-24, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

26. The method of any one of claims 1-24, wherein the patient has undergone prior systemic therapy for the MTAP-resistant gastrointestinal cancer.

27. The method of claim 26, wherein the prior systemic therapy is FOLFIRINOX.

28. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective amount of each of the following: (a) Compound G: or its pharmaceutically acceptable salt; and (b)(i) A combination of irinotecan, (ii) 5-fluorouracil, (ii) leucovorin, and (iv) oxaliplatin.

29. The method of claim 28, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

30. The method of claim 28, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

31. The method of any one of claims 28-30, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

32. The method of any one of claims 28-30, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

33. The method of claim 32, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

34. The method of any one of claims 28-33, wherein compound G is applied as a free base.

35. The method of any one of claims 28-34, the method comprising administering 500 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

36. The method of any one of claims 28-34, the method comprising administering 600 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

37. The method of any one of claims 28-34, the method comprising administering 800 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

38. The method of any one of claims 28-34, the method comprising administering 900 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

39. The method of any one of claims 28-34, the method comprising administering 1200 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

40. The method of any one of claims 28-39, wherein compound G is administered to the patient once daily.

41. The method of any one of claims 28-40, wherein compound G is administered orally.

42. The method of any one of claims 28-41, wherein compound G is administered as a tablet formulation.

43. The method of any one of claims 28-42, wherein the method comprises administering 150 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Irinotecan twice.

44. The method of any one of claims 28-43, wherein the method comprises administering 2400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 5-Fluorouracil twice.

45. The method of any one of claims 28-44, wherein the method comprises administering 400 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Two doses of folinic acid.

46. ​​The method of any one of claims 28-45, wherein the method comprises administering 85 mg / m² to the patient via IV during a 28-day treatment cycle. 2 Oxaliplatin twice.

47. The method of any one of claims 28-46, wherein the irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin are administered on days 1 and 15 of a 28-day treatment cycle.

48. The method of any one of claims 28-33 and 40-42, the method comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, of which 150 mg / m 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle.

49. The method of any one of claims 28-33 and 40-42, the method comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, of which 150 mg / m 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle.

50. The method of any one of claims 28-33 and 40-42, the method comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, of which 150 mg / m 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle.

51. The method of any one of claims 28-33 and 40-42, the method comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, of which 150 mg / m 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle.

52. The method of any one of claims 28-33 and 40-42, the method comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) (i) 150 mg / m 2 Irinotecan, (ii) 2400 mg / m 2 5-Fluorouracil, (iii) 400 mg / m 2 Folic acid, and (iv) 85 mg / m 2 The combination of oxaliplatin, of which 150 mg / m 2 Irinotecan, 2400 mg / m 2 5-Fluorouracil, 400 mg / m 2 Folic acid and 85 mg / m 2 Oxaliplatin was administered on days 1 and 15 of a 28-day treatment cycle.

53. The method according to any one of claims 48-52, wherein compound G is applied as a free base.

54. The method of any one of claims 28-53, wherein the patient is a treatment-naïve patient with MTAP-resistant gastrointestinal cancer.

55. A method for treating MTAP-resistant gastrointestinal cancer in a patient in need, the method comprising administering to the patient a therapeutically effective amount of each of the following: (a) Compound G: or its pharmaceutically acceptable salt; (b) Gescitabine; (c) Cisplatin; and (d) Anti-PD1 antibody or anti-PDL1 antibody.

56. The method of claim 55, wherein the MTAP-ineffective gastrointestinal cancer is locally advanced.

57. The method of claim 55, wherein the MTAP-ineffective gastrointestinal cancer is metastatic.

58. The method of any one of claims 55-57, wherein the MTAP-ineffective gastrointestinal cancer is biliary tract cancer.

59. The method of any one of claims 55-57, wherein the MTAP-ineffective gastrointestinal cancer is pancreatic cancer.

60. The method of claim 59, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

61. The method of any one of claims 55-60, the method comprising administering 500 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

62. The method of any one of claims 55-60, the method comprising administering 600 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

63. The method of any one of claims 55-60, the method comprising administering 800 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

64. The method of any one of claims 55-60, the method comprising administering 900 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

65. The method of any one of claims 55-60, the method comprising administering 1200 mg of compound G or a salt thereof to the patient based on the free base weight of compound G.

66. The method according to any one of claims 55-65, wherein compound G is applied as a free base.

67. The method of any one of claims 55-66, wherein compound G is administered once daily.

68. The method of any one of claims 55-67, wherein compound G is administered orally.

69. The method of any one of claims 55-68, wherein compound G is administered as a tablet formulation.

70. The method of any one of claims 55-69, wherein the anti-PDL1 antibody is administered to the patient.

71. The method of any one of claims 55-69, wherein the anti-PD1 antibody is administered to the patient.

72. The method of claim 71, wherein the anti-PD1 antibody is pembrolizumab.

73. The method of claim 72, wherein the method comprises administering 200 mg of pembrolizumab once via intravenous administration to the patient during a 21-day treatment cycle.

74. The method of any one of claims 55-73, wherein the method comprises administering 1000 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Giscitabine.

75. The method of any one of claims 55-74, wherein the method comprises administering 25 mg / m² to the patient via IV on days 1 and 8 of each 21-day treatment cycle. 2 Cisplatin.

76. The method of any one of claims 55-60 and 67-69, the method comprising administering to the patient (a) 500 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

77. The method of any one of claims 55-60 and 67-69, the method comprising administering to the patient (a) 600 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

78. The method of any one of claims 55-60 and 67-69, the method comprising administering to the patient (a) 800 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

79. The method of any one of claims 55-60 and 67-69, the method comprising administering to the patient (a) 900 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

80. The method of any one of claims 55-60 and 67-69, the method comprising administering to the patient (a) 1200 mg of compound G or a salt thereof once daily, based on the free base weight of compound G, and (b) 1000 mg / m². 2 Gemcitabine, (c) 25 mg / m 2 Cisplatin, and (d) 200 mg pembrolizumab, administered via IV on days 1 and 8 of each 21-day treatment cycle at a dose of 1000 mg / m². 2 Gemcitabine and 25 mg / m 2 Cisplatin, and wherein the pembrolizumab is administered once intravenously during a 21-day treatment cycle.

Citation Information

Patent Citations

  • Anti-PD-1 antibodies for treatment of lung cancer

    US11292842B2

  • PD-1 specific antibodies and uses thereof

    US20110171215A1

  • PD-1 specific antibodies and uses thereof

    US20110171220A1

  • Human Anti-PD-1, PD-l1, and PD-l2 antibodies and uses therefor

    US20110271358A1

  • Antibodies against PD-1

    US7488802B2